# Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer

> **NCT01599832** · NA · TERMINATED · sponsor: **University of Chicago** · enrollment: 20 (actual)

## Conditions studied

- Clear Cell Renal Cell Carcinoma
- Recurrent Renal Cell Cancer
- Stage IV Renal Cell Cancer

## Interventions

- **DRUG:** pazopanib hydrochloride
- **OTHER:** laboratory biomarker analysis
- **PROCEDURE:** dynamic contrast-enhanced magnetic resonance imaging
- **OTHER:** pharmacogenomic studies

## Key facts

- **NCT ID:** NCT01599832
- **Lead sponsor:** University of Chicago
- **Sponsor class:** OTHER
- **Phase:** NA
- **Study type:** INTERVENTIONAL
- **Status:** TERMINATED
- **Start date:** 2012-06
- **Primary completion:** 2015-12
- **Final completion:** 2015-12
- **Target enrollment:** 20 (ACTUAL)
- **Why stopped:** Poor accrual
- **Last updated:** 2017-06-08

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT01599832

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT01599832, "Dynamic Contrast-Enhanced Magnetic Resonance Imaging in Measuring Effects of Pazopanib Hydrochloride in Patients With Metastatic Kidney Cancer". Retrieved via AI Analytics 2026-05-27 from https://api.ai-analytics.org/clinical/NCT01599832. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*